EXCEL-Punjabi: A Culturally Tailored Exercise Oncology Pilot Feasibility Intervention (EXCEL-Punjabi)

June 8, 2026 updated by: University of Calgary

EXCEL-Punjabi: Tailored Exercise Oncology for the South Asian Population

The goal of this pilot feasibility study is to explore the feasibility and exploratory effects of a culturally-tailored exercise oncology intervention in Punjabi-speaking individuals of South Asian heritage and their support persons. The main questions it aims to answer are:

  1. What is the feasibility and acceptability of the EXCEL-Punjabi intervention?
  2. What are the exploratory effects (i.e., psychosocial and physical changes) before and after program delivery?

Participants will take part in a 12-week exercise oncology intervention consisting of twice weekly hour long multimodal circuit-based exercise sessions. They will also complete questionnaires and functional fitness assessments pre- and post- intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
12

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 1N4
        • Genesis Centre Calgary

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Punjabi-speaking
  • Self-identified as being of South Asian heritage
  • over the age of 18
  • pre-, post-, or currently receiving cancer treatment or a support person of an individual living with and beyond cancer
  • cleared to participate in, at minimum, mild intensity exercise by a Clinical Exercise Physiologist
  • Able to provide informed consent

Exclusion Criteria:

  • under the age of 18
  • not cleared to exercise by a Clinical Exercise Physiologist

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: EXCEL-Punjabi
Culturally Tailored Exercise Oncology Intervention
Behavioral: EXCEL-Punjabi
Culturally Tailored Exercise Oncology Intervention

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Measurement Completion
Time Frame: Baseline to the end of the intervention (12 weeks)
Participants who completed all pre- and post- questionnaires and functional assessments
Baseline to the end of the intervention (12 weeks)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Referrals
Time Frame: Baseline to end of intervention (12 weeks)
Number of participants referred to intervention
Baseline to end of intervention (12 weeks)
Consented
Time Frame: Recruitment to end of intervention (12 weeks)
Number of participants who consented to participate in the intervention
Recruitment to end of intervention (12 weeks)
Enrolled
Time Frame: Baseline (week 0)
Number of participants who enrolled (i.e. completed baseline assessments)
Baseline (week 0)
Attendance
Time Frame: Baseline to end of intervention (12 weeks)
Intervention Attendance
Baseline to end of intervention (12 weeks)
Adverse Events
Time Frame: Baseline to end of intervention (12 weeks)
Using the standardized Common Terminology Criteria for Adverse Events Version 6.0
Baseline to end of intervention (12 weeks)
Time Required to Deliver and Implement Intervention
Time Frame: From recruitment to end of intervention (12 weeks)
Time requirement to deliver intervention
From recruitment to end of intervention (12 weeks)
Physical Activity Level
Time Frame: Baseline to end of intervention (12 weeks)
The Godin Leisure Time Exercise Questionnaire is used to determine subjective levels of physical activity in each participant. Participants report how many times per week they partake in mild, moderate, and/or strenuous exercise. Higher scores indicate a more physically active lifestyle.
Baseline to end of intervention (12 weeks)
Cancer related symptoms
Time Frame: Baseline to end of intervention (12 weeks)
Change in Edmonton Symptom Assessment Scale - revised: cancer. Scale is from 0-10, where 0 means the symptom is absent and 10 means the worst possible severity of the symptom is being experienced.
Baseline to end of intervention (12 weeks)
Health Related Quality of Life
Time Frame: Baseline to end of intervention (12 weeks)
Change in EuroQual - 5Dimensions (EQ-5D) tool - first section is a questionnaire; last section uses a scale from 0-100, where 0 means the worst health imaginable and 100 means the best health imaginable.
Baseline to end of intervention (12 weeks)
Fatigue
Time Frame: Baseline to end of intervention (12 weeks)
Change in Functional Assessment of Chronic Illness Therapy - Fatigue subscale - scale is from 0-4, where 0 means "not at all" and 4 means "very much".
Baseline to end of intervention (12 weeks)
Cancer Related Quality of Life
Time Frame: Baseline to end of intervention (12 weeks)
A 5-point Likert scale (0 = not at all, to 4 = very much) to track wellbeing over the course of the cancer journey.
Baseline to end of intervention (12 weeks)
Exercise Barriers Self-Efficacy
Time Frame: Baseline to end of intervention (12 weeks)
Exercise barriers and facilitators questionnaire
Baseline to end of intervention (12 weeks)
Cognition
Time Frame: Baseline to end of intervention (12 weeks)
Cancer related cognition using the Functional Assessment of Cancer Therapy - Cognition questionnaire. A 37-item, self-report questionnaire used to evaluate how cancer patients perceive their own cognitive abilities
Baseline to end of intervention (12 weeks)
Aerobic Capacity
Time Frame: Baseline to end of intervention (12 weeks)
In-person participants will be assessed on change in 6-minute walk test (m) results
Baseline to end of intervention (12 weeks)
Aerobic Capacity
Time Frame: Baseline to end of intervention (12 weeks)
Online participants will be assessed with change in the 2-minute step test (number of steps) results.
Baseline to end of intervention (12 weeks)
Lower body strength
Time Frame: Baseline to end of intervention (12 weeks)
Change in sit-to-stand (number of repetitions in 30 seconds)
Baseline to end of intervention (12 weeks)
Upper extremity flexibility
Time Frame: Baseline to end of intervention (12 weeks)
Change in active shoulder flexion range of motion (degrees)
Baseline to end of intervention (12 weeks)
Balance
Time Frame: Baseline to end of intervention (12 weeks)
Change in one legged stance test (seconds)
Baseline to end of intervention (12 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Calgary

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Canadian Institutes of Health Research (CIHR)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 12, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 12, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 11, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 11, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HREBA.CC-25-0150

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Aggregate and participant-level results are reported within publications, but there is no formal plan for external IPD sharing. With a small sample size from a specific cultural group, there may be risk of re-identification.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on EXCEL-Punjabi

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings